A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients
A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients
复制标题
DOI：
10.1007/s10156-009-0715-7
复制
发表时间：
2009-12-01
影响因子：
2.2
通讯作者：
Iwata, Satoshi
中科院分区：
文献类型：
--
作者：
Matsubara, Keita;Morozumi, Miyuki;Iwata, Satoshi
近年来，耐大环内酯类肺炎支原体（MR-M）的流行增加。肺炎）已成为日本的一个重要问题。共分离出94株M. pneumoniae，并测定了大环内酯类和其他抗菌药物对这些菌株的最低抑菌浓度（MIC）。我们还对大环内酯类药物治疗MR-M的疗效进行了比较性临床评价。肺炎支原体感染和大环内酯敏感性肺炎支原体感染（MS-M.肺炎）。94株M.肺炎支原体64例（68.1%）。MR-M 30例（31.9%）。pneumoniae菌株该临床研究包括对47例MS-M儿童病例的评估。肺炎和22例MR-M的儿科病例。肺炎。患者的人口统计学资料，如性别、年龄、从感染发作到首次检查的时间、实验室检查结果、诊断和症状的严重程度，在两个研究组之间没有显着差异。然而，大环内酯类药物治疗MS-M的有效率为91.5%。MR-M感染率为22.7%。pneumoniae组与对照组比较，差异有统计学意义（P < 0.01）。虽然M.肺炎支原体感染通常被认为是一种可治疗的疾病，大环内酯类耐药肺炎支原体菌株的流行率不断增加。肺炎已成为儿科患者的重要临床问题，因此有必要仔细考虑MR-M的适当抗菌治疗。肺炎感染。
In recent years, the increased prevalence of macrolide-resistant Mycoplasma pneumoniae (MR-M. pneumoniae) has become a significant issue in Japan. We isolated 94 strains of M. pneumoniae, and determined the minimum inhibitory concentrations (MICs) of macrolides and other antimicrobial agents for these strains. We also performed a comparative clinical evaluation of macrolide efficacy for cases of MR-M. pneumoniae infections and cases of macrolide-sensitive Mycoplasma pneumoniae infections (MS-M. pneumoniae). Of the 94 isolates of M. pneumoniae, 64 (68.1%) were classified as MS-M. pneumoniae and 30 (31.9%) as MR-M. pneumoniae strains. The clinical study included an assessment of 47 pediatric cases of MS-M. pneumoniae and 22 pediatric cases of MR-M. pneumoniae. The patient demographics, such as sex, age, the period from the onset of the infection to the first examination, laboratory findings, diagnosis, and the severity of symptoms, showed no significant difference between the two study groups. However, the efficacy of macrolide treatment was 91.5% for MS-M. pneumoniae and 22.7% for MR-M. pneumoniae, a statistically significant difference (P < 0.01). Although M. pneumoniae infection is generally considered a treatable condition, the increasing prevalence of macrolide-resistant strains of M. pneumoniae has become a significant clinical issue in pediatric patients, and it is therefore necessary to give careful consideration to the appropriate antimicrobial therapy for MR-M. pneumoniae infection.